Cytosin-Arabinosid
Acute Myeloid Leukemia, T(16;16)(P13.1;Q22)
M.D. Anderson Cancer CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Acute Myeloid Leukemia, T(16;16)(P13.1;Q22) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine M.D. Anderson Cancer Center | Phase 2 | CCC |
Gemtuzumab Ozogamicin M.D. Anderson Cancer Center | Phase 2 | CCC |
Idarubicine M.D. Anderson Cancer Center | Phase 2 | CCC |
Decitabine M.D. Anderson Cancer Center | Phase 2 | CCC |
FILGRASTIM-SNDZ M.D. Anderson Cancer Center | Phase 2 | CC |
Same molecule, other indications
Cytosin-Arabinosid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →